Obagi Retinol + PHA Refining Night Cream Review

Retinol has the best evidence of any over-the-counter anti-aging ingredient and one of the worst retention rates. People start it, flake for three weeks, and stop. Obagi, whose Obagi360 Retinol 1.0 is exactly the kind of product that causes that cycle, launched the Retinol + PHA Refining Night Cream in 2025 as an answer to the drop-out rather than another rung on the strength ladder, and the ingredient list reads like a checklist of everything a formulator would add to keep someone using a retinoid past week three.

The first thing to notice is the order. Gluconolactone, a polyhydroxy acid, is third in the list, ahead of the glycerin and every emollient; retinol is thirteenth, behind the shea butter extract and the hydrogenated lecithin that most likely carries it. That is a PHA cream with a retinol in it, not the other way round, and the arrangement is deliberate. Polyhydroxy acids are the large, slow, water-binding cousins of glycolic acid, and the published work on them found they could be combined with retinoic acid without the irritation a classical AHA would add. Here the gluconolactone does two jobs at once: it clears the loosened surface cells that would otherwise show as retinol flaking, and it hydrates while doing it. The retinol, at an undisclosed percentage, is delivered in what Obagi calls an entrapment system that releases it gradually through the night, which flattens the irritation curve of a free retinol at the same dose.

Around those two is the hydration cast Obagi counts as eight: caprylic/capric triglyceride second, sunflower seed oil sixth, glycerin, shea butter extract, sodium hyaluronate directly after the retinol, jojoba esters, tocopherol and squalane. It is a proper emollient cream, fragrance-free and alcohol-free, with cetearyl and cetyl alcohols for body and a little dimethicone for slip. The finish is a soft matte-satin cushion that most skin will happily wear as its only night product, and that is the design brief: one step, no separate moisturizer, no reason to skip it.

In use it behaves like a good moisturizer that turns out to be doing more. The first week is smooth and uneventful, the PHA softening texture immediately. In the second and third weeks some users see fine flaking on the cheeks or around the nose as the retinol takes hold, and the gluconolactone smooths most of it away before it becomes the sheet-peeling that sends people back to the drawer. By four weeks the surface is noticeably refined, and Obagi's own eight-week clinical test, run across 2024 and 2025, reported that nine in ten participants saw visible smoothing and fewer blemishes at that point, with most seeing more even tone and softer fine lines at eight weeks, and instrumental improvements of 29% in smoothness and 10% in tone evenness. Those are brand figures, on file rather than published, but they are an actual clinical test with instrumental endpoints, which is more than most retinol creams bring, and they align with what retinol and PHAs are independently known to do on those timescales.

What the cream will not tell you is how much retinol you are getting, and that is the honest reservation. The evidence for retinol's effect on fine lines and collagen comes from studies at defined concentrations, and an undisclosed dose in an entrapment system leaves the buyer trusting the four-week results rather than the label. Obagi's Retinol 1.0 exists for people who want a stated strength; this cream is for people who would rather have results they can tolerate than a number they can quote. Very oily skin will also find the sunflower-and-shea base heavier than it wants, cetyl esters and shea carry a mild congestion risk, and the price is the standing Obagi objection: $135 for 1.7 oz is prestige night cream money, though a hazelnut-sized dose stretches the bottle to two or three months, around $45 to $65 a month.

There is also a quieter argument for the combination that the marketing does not make. Retinol and gluconolactone address the same two complaints, dull texture and clogged, uneven skin, by different routes, the retinoid from below by normalising how cells mature and the PHA from above by clearing what has already died, and in a single cream the two reinforce each other on the four-to-eight-week horizon Obagi's test used. That is why the blemish figure in the test is worth noticing: it is the kind of result a retinoid alone produces slowly and a PHA alone produces superficially, and together they produce it faster, which for the adult with congestion and early lines is the actual point of buying one product instead of two.

For whom, then? First-time retinol users who have heard the horror stories, sensitive or dry skin that has quit a retinoid before, and anyone who wants one evening product that treats and moisturizes without a ritual of layers. For that audience it is one of the more carefully engineered entry points on the market. For experienced retinoid users with resilient skin, the undisclosed dose and the rich base are two reasons to keep using whatever stronger, cheaper product they already tolerate.